Immune design corp. (IMDZ)
CashFlow / Yearly
Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Operating activities
Net loss

-54,758

-51,862

-53,530

-39,445

-34,151

-15,975

-10,840

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

346

351

304

243

238

407

548

Amortization of premium/discount on investments

561

26

-126

0

0

-

-

Impairment of inventory

1,200

0

0

-

-

-

-

Stock-based compensation

7,276

8,633

9,283

6,297

1,344

255

244

Revaluation of convertible preferred stock warrant liability

-

-

-

-

4,277

955

0

Other

-

-

-

-

-

-94

-23

Changes in operating assets and liabilities:
Accounts receivable

58

130

-455

-998

1,883

-426

452

Inventory

652

77

594

-12

8

-109

252

Prepaid expenses

184

-975

892

1,021

454

-8

-152

Restricted cash

-

-

-

0

-

-

-

Other assets

-1,348

-22

3,059

0

0

-

-

Security deposit

-

-

-

0

-

-

-

Accounts payable

-856

-2,225

1,485

-3,829

6,037

-213

504

Accrued liabilities

1,181

1,203

976

-519

3,424

-453

623

Accrued litigation-related settlement

-6,000

-1,250

7,250

0

0

-

-

Deferred revenue

0

-2,545

2,496

-

-

-

-

Deferred revenue

-

-

-

-510

-

-

-

Deferred rent and other noncurrent liabilities

8

72

-40

-27

507

89

-128

Net cash used in operating activities

-51,666

-46,859

-35,740

-37,801

-20,669

-14,298

-9,578

Investing activities
Purchases of property and equipment

390

428

133

427

344

175

294

Purchases of short-term investments

34,685

71,611

102,288

-

-

-

-

Maturities of short-term investments

86,000

65,000

40,000

0

0

-

-

Purchases of short-term investments

-

-

-

0

0

-

-

Proceeds from the sale of property and equipment

-

-

-

-

-

43

0

Net cash provided by (used in) investing activities

50,925

-7,039

-62,421

-427

-344

-132

-294

Financing activities
Issuance of common stock in public offering, net of offering costs

0

86,624

30,310

75,359

57,807

0

0

Proceeds from exercise of preferred stock warrants

-

-

-

-

8,150

0

0

Proceeds from issuances of common stock under stock-based compensation plans

228

714

144

436

23

6

-

Proceeds from sale of convertible preferred stock, net of cash paid for issuance costs

-

-

-

-

-

29,668

10,615

Proceeds from sale of convertible preferred stock warrants

-

-

-

-

-

2,381

0

Proceeds from exercise of stock options

-

-

-

-

-

-

11

Net cash provided by financing activities

228

87,338

30,454

75,795

65,980

32,055

10,626

Net (decrease) increase in cash and cash equivalents

-513

33,440

-67,707

-

-

-

-

Supplemental cash flow information
Unpaid stock offering costs

0

48

0

0

-

-

-

Net (decrease) increase in cash and cash equivalents

-

-

-

37,567

44,967

17,625

754